$0.327
-0.005 (-1.66%)At close
HRTX News
HRTX Events
Heron Therapeutics Loses Patent Litigation, Plans to Appeal
Heron Therapeutics announced that the U.S. District Court for the District of Delaware issued a decision in the patent litigation between Heron and Azurity Pharmaceuticals, Inc., Azurity Pharmaceuticals India and Slayback Pharma, with respect to Cinvanti injectable emulsion, holding that the asserted claims of company's U.S. Patent Nos. 12,115,255 and 12,290,520 are invalid. This decision has no impact on any prior settlement agreement related to Cinvanti injectable emulsion or Aponvie injectable emulsion. Heron intends to appeal the decision to the United States Court of Appeals for the Federal Circuit, a court that specializes in patent disputes.
Heron Q1 Revenue at $34.71M, Below Consensus
Reports Q1 revenue $34.71M, consensus $36.72M. "Despite typical first-quarter seasonality and unusual weather-related disruption early in the quarter, we saw a clear recovery in February and March," said Craig Collard, Chief Executive Officer of Heron. "Our Acute Care franchise continues to perform with strong year-over-year growth, and we remain confident in our full-year framework as deferred elective procedures return and our commercial catalysts such as IGNITE 2.0, unique J-Codes, and planned sales force expansion for the Acute Care franchise continue to build through 2026."
Company Adjusts FY26 EBITDA Outlook to $10M-$20M
Backs FY26 adjusted EBITDA view $10M-$20M.
Heron Reports Q4 Revenue of $40.588M, Beating Consensus
Reports Q4 revenue $40.588M, consensus $39.53M. "As demonstrated in today's release, we are entering 2026 with exceptional momentum. The fourth quarter delivered the strongest results in the history of Heron's Acute Care franchise, underscoring the success of the strategic decisions we implemented to unlock the full potential of these assets," said Craig Collard, Chief Executive Officer of Heron. "The milestones achieved in 2025, particularly for ZYNRELEF - including enhanced distributor-partner incentives, the seamless completion of the Vial Access Needle transition, and CMS approval of a product-specific J-Code - are already accelerating adoption and strengthening our competitive position in a large and underpenetrated market."
Sees FY26 Adjusted EBITDA of $10M to $20M
Sees FY26 adjusted EBITDA $10M to $20M
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。